The Zhitong Finance App learned that Danish pharmaceutical giant Novo Nordisk (NVO.US) has experienced a major R&D setback. The company announced on Friday that its much-publicized new cardiac drug ziltivekimab failed to reach a major end in a large-scale late-stage clinical trial. The news caused its stock price to plummet by more than 10% in the intraday period.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.